CRVS Corvus Pharmaceuticals Inc.

3.26
+0.26  (+9%)
Previous Close 3
Open 3.06
Price To Book 1.07
Market Cap 95,812,704
Shares 29,390,400
Volume 74,846
Short Ratio
Av. Daily Volume 114,117
Stock charts supplied by TradingView

NewsSee all news

  1. Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data at SITC November 2018 noted 1/33 PRs on monotherapy and 1/35 on combo.
CPI-444
Solid tumors - cancer
Phase 1/1b updated data due at SITC November 8, 2019 from 3:45 pm ET.
CPI-006
Solid tumors
Phase 1/1b data due late 2019 or early 2020.
CPI-818
Peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)

Latest News

  1. Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted